Advanced Drug Delivery Systems

This study evaluates DCMax, a delayed Cmax drug delivery system, showing it delays peak plasma concentration and sustains release in healthy volunteers.

This paper develops a PEG-based hydrogel for intranasal drug delivery that forms in situ without physiological triggers, improving drug residence time and bioavailability.

This paper develops an intranasal liposomal NorBNI formulation that selectively delivers KOR antagonists to the brain, reducing systemic exposure and off-target effects while improving pain-induced negative affect.

This study develops a hydrogel-based vaccine delivery system that enhances immune responses and reduces reactogenicity in aged mice compared to Shingrix.

This study evaluates suprachoroidal delivery of AXT107 microparticles for treating retinal and choroidal vascular diseases, showing reduced neovascularization and favorable safety.

This paper demonstrates that chitosan-coated alginate microcapsules can protect cell-free gene expression lysates and proteins from degradation in the GI tract and enable controlled release in simulated intestinal conditions.

This paper develops a hydrogel that enables subcutaneous delivery of vesicant antibody-drug conjugates by confining them in a depot, reducing tissue damage while maintaining antitumor efficacy.

The paper develops a microfluidic device for precise intranasal drug delivery in freely-moving mice and validates its use for studying cocaine's effects.

This paper develops single and combined topical inserts for bacterial STI and HIV prevention, showing effective drug release and stability.

This paper introduces a synthetic intrinsically disordered protein coating that enhances oral delivery of peptide drugs by protecting them from gastric acid and enabling targeted intestinal release.

This study develops CBD-loaded polymeric micelles for nose-to-brain delivery in ASD, showing improved brain CBD concentration and behavioral symptom improvement in a rat model.

This paper develops an injectable hydrogel platform with poly(orthoester) microparticles for long-term, zero-order drug release, demonstrating in vitro and in vivo efficacy for up to 12 months.

This study develops and validates a localized delivery system for infliximab in ulcerative colitis, showing improved therapeutic efficacy and reduced systemic absorption.

This study demonstrates that NosaPlugs nasal inserts can deliver memantine to the brain in mice, providing a proof-of-concept for nose-to-brain drug delivery.

This paper develops multilayer polymeric films for buccal delivery of GLP-1-RA and GDC, showing that triple-layer films provide sustained release and better mucosal compatibility than dual-layer films.

This study develops synthetic mucin-based hydrogels for localized delivery of anti-TNF- antibodies in IBD, showing improved retention and reduced systemic exposure.

This study evaluates NoriZite(R), a nasal spray based on gellan polysaccharide, showing a 4-hour half-life and up to 6-hour retention in the nasal cavity, suggesting potential as a long-lasting barrier against airborne infections.

This study demonstrates enzyme-functionalized microparticles that locally open the inner limiting membrane to enhance nanoparticle transport to retinal tissue in a porcine model.

This paper develops an oral drug delivery system using drug-loaded nanogels encapsulated in a mucoadhesive shell, showing improved controlled release and oral half-life compared to free drug.

This paper develops a computational model to optimize multi-layered microcapsules for controlled drug release in treating wet AMD, showing polymer thickness and chitosan layer impact release dynamics.

This study identifies small molecules that selectively bind to mucins in the gastrointestinal tract, enhancing localized drug delivery to the small intestine and stomach.

The paper develops a hybrid Taguchi/machine learning framework to optimize particulate drug delivery systems, achieving high predictive accuracy and revealing key formulation factors.

The paper develops MECS NPs with controlled surface charge to enhance mucus transport and cell binding for improved mucosal drug delivery.

The paper develops a mathematical model and statistical analysis to predict therapeutic release from contact lenses based on lens and drug properties.

This paper develops a brain delivery system using RVG29-conjugated chitosan nanoparticles to deliver kisspeptin agonists and antagonists, showing enhanced brain accumulation and effective modulation of reproductive functions.

This paper develops a thermoresponsive liposomal depot that releases drugs in response to physiological cues, demonstrating prolonged analgesia in rats and dogs.

This study evaluates the pharmacological and safety profile of MP-004 after topical eye drops in mice, rabbits, and pigs, showing effective retinal concentrations and minimal systemic exposure.

This study develops a diet gel-based oral drug delivery system for controlled dosing of PLX5622 and Tamoxifen in mice, achieving high microglia depletion and inducible Cre recombination.

This study develops intranasal sertraline formulations to reduce systemic exposure while maintaining brain delivery, showing comparable brain exposure at half the dose compared to oral administration in mice.

This study develops a photocrosslinked hyaluronic acid hydrogel for nasal drug delivery, showing improved mucoadhesion and stability compared to uncrosslinked versions.